SMMT NASDAQ Week ended 07 Aug 2026

Weekly Investor Report

Summit Therapeutics PLC · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 13.96 USD
7.2% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -14.0% below the Trend Line and sits at 9.6% of its 52-week range. The latest completed week returned 7.2%, after a -8.5% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 40/100 conviction, while the latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 67d.

Setup score 20 out of 100
Latest Close 13.96 USD 7 Aug 2026
1W Return 7.2% latest completed week
4W Return -8.5% short-term follow-through
12W Return -17.2% quarterly tape
Trend Breadth 11.5% 6 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • Latest weekly return ranks in the strongest part of its sector group.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 7.2% Latest completed week; four-week move -8.5%. Indicator stack 6/29 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bullish 40/100 conviction; expected move 8.0%. News sentiment 52/100 65 relevant articles in the latest sentiment read. Event risk 67d Next report is scheduled for 19 Oct 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -14.0% below the Trend Line and sits at 9.6% of its 52-week range. The latest completed week returned 7.2%, after a -8.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0212-week average 0.19

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure4/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.02Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -8.5% over four weeks, -17.2% over 12 weeks, and -51.3% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W7.2%
4W-8.5%
12W-17.2%
26W-6.9%
52W-51.3%
Active trend streak0 weeks
Active weeks in one year6
Trend breadth11.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.93Latest activity-pressure read.
Pressure change-55.8%Four-week change in activity pressure.
Leadership-32.39Latest relative-leadership reading.
RS change-1.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 30 Jun 2026 Field coverage 67% Model confidence 67%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength37/100Blend of value, momentum, and quality. Underlying universe rank 64; rank 1 is best.
Value44/100Relative valuation strength. Underlying universe rank 57; rank 1 is best.
Quality41/100Profitability and accounting quality. Underlying universe rank 60; rank 1 is best.
Momentum44/100Medium-term price momentum. Underlying universe rank 57; rank 1 is best.
Growth44/100Revenue and earnings growth. Underlying universe rank 57; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-4.0%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-280.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-5.4%
Net share repurchases relative to market value.
Shareholder yield
-5.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

SMMT shows bullish options pressure with a 40/100 conviction score, put-call volume ratio of 0.53, expected move of 8.0%, and Sharemaestro trend signal inactive.

Conviction40/100
Expected move8.0%
Put/call volume0.53
Pressure38
Speculation40
Volatility88
Trend agreement25
Open options detail
Insider activity6 / 0

6 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment52/100

Weighted news tone is neutral across 65 relevant articles.

20 positive · 31 neutral · 14 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings67dNext report is scheduled for 19 Oct 2026; event risk rises as the date approaches.
Options expected move8.0%Nearest-chain priced movement where available.
52-week drawdown-53.5%Distance below the 52-week high.
13-week volatility6.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+27.9%Week of 17 Apr.
Worst week-27.0%Week of 1 May.
Latest week+7.2%Week of 7 Aug.

Shape of recent returns

Strong gains10
Modest gains2
Flat weeks0
Modest losses6
Sharp losses8
Recent vol6.7%13-week weekly-return volatility.
Base vol9.7%52-week weekly-return volatility.
Up/down split21/31Count of positive and negative weeks in the 52-week window.
Average skew7.7% / -6.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape20/100

Trend, activity pressure, participation, and risk combine to a 20/100 tape read.

 Indicator analysis16/100

Latest 12-week confirmation: trend 0/12, activity pressure 4/12, relative leadership 0/12.

Activity pressure 0.02; No reversal markers Factors40/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 83; Small Cap Core rank 58 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options49/100

SMMT shows bullish options pressure with a 40/100 conviction score, put-call volume ratio of 0.53, expected move of 8.0%, and Sharemaestro trend signal inactive.

Bullish · Call-side pressure · Expected move 8.0% Sentiment52/100

Weighted news tone is neutral across 65 relevant articles.

SMMT|Summit Therapeutics Inc|Price:13.030|Chg%:-0.410 Insiders6 / 0

6 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings67d

Next report is scheduled for 19 Oct 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 202613.96 USD7.2%16.23 USD14.37 USD-0.93-32.3915.2MOff
31 Jul 202613.02 USD-4.7%16.42 USD14.29 USD-0.96-35.0820.8MOff
24 Jul 202613.66 USD-1.1%16.57 USD14.22 USD-0.82-32.8522.3MOff
17 Jul 202613.81 USD-9.4%16.72 USD14.15 USD-0.70-34.5015.3MOff
10 Jul 202615.25 USD-1.1%16.86 USD14.07 USD-0.60-31.8514.6MOff
3 Jul 202615.42 USD10.1%16.93 USD13.99 USD-0.45-30.8922.3MOff
26 Jun 202614.01 USD1.9%17.03 USD13.90 USD-0.31-37.5329.1MOff
19 Jun 202613.75 USD-1.9%17.16 USD13.83 USD-0.12-42.0828.7MOff
12 Jun 202614.01 USD-5.1%17.24 USD13.76 USD0.11-40.1538.3MOff
5 Jun 202614.77 USD-15.8%17.37 USD13.68 USD0.24-36.1345.9MOff
29 May 202617.54 USD5.5%17.49 USD13.60 USD0.48-28.3319.0MOff
22 May 202616.62 USD-1.5%17.53 USD13.49 USD0.61-30.5922.0MOff
15 May 202616.87 USD-6.7%17.62 USD13.40 USD0.92-29.8113.3MOn
8 May 202618.08 USD12.2%17.76 USD13.30 USD1.29-25.9521.4MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context